Results 281 to 290 of about 732,131 (343)
Some of the next articles are maybe not open access.

Oligonucleotide Charge Reversal: 2′-O-Lysylaminohexyl Modified Oligonucleotides

Nucleosides, Nucleotides & Nucleic Acids, 2007
A novel cationic building nucleoside building block designed for antisense and siRNA oligonucleotides is presented. Protected L-lysine was coupled to 2'-O-aminohexyluridine and the resulting nucleoside was phosphitylated for automated oligonucleotide synthesis.
Winkler, Johannes, Noe, Christian
openaire   +3 more sources

Oligonucleotide Therapy

2017
Oligonucleotides (ONs), the focus of the chapter herein, are mostly known for their utility to selectively manipulate RNA processing by increasing or decreasing target gene levels, in particular by inducing enzymatic RNA degradation, blocking or mimicking miRNAs, inhibiting mRNA translation or modulating pre-mRNA splicing.
Covello, Giuseppina   +1 more
openaire   +2 more sources

Immunostimulatory Oligonucleotides

Recent Patents on Inflammation & Allergy Drug Discovery, 2011
RNA-protein interactions have been characterized often. Above all, the proteins which are associated with the studied RNA should be precisely identified. The pharmaceutical compositions containing nucleic acids and/or other compounds can be administered by any suitable route for administering medications. The immunostimulatory oligonucleotides play the
openaire   +2 more sources

Oligonucleotide therapeutics

Trends in Biotechnology, 1992
Recent studies have focused on the ability of oligonucleotides to affect the genetic processes of many organisms, including viruses. Hence, oligonucleotides may represent a future source of biotechnologically derived compounds of therapeutic importance for diseases such as cancer and AIDS.
openaire   +2 more sources

FDA-Approved Oligonucleotide Therapies in 2017

open access: yesMolecular Therapy, 2017
Oligonucleotides (oligos) have been under clinical development for approximately the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs.
C. Stein, D. Castanotto
exaly   +2 more sources

Oligonucleotide therapy

Current Opinion in Biotechnology, 1992
Rapid progress in oligonucleotide therapeutics has continued over the past year as major programs established in the past four years have grown and begun to be productive. Important advances were reported in the medicinal chemistry of oligonucleotides and in understanding their pharmacodynamic properties.
openaire   +2 more sources

Current State of Oligonucleotide Characterization Using Liquid Chromatography-Mass Spectrometry: Insight into Critical Issues.

Journal of the American Society for Mass Spectrometry, 2020
As interests increase in oligonucleotide therapeutics, there has been a greater need for analytical techniques to properly analyze and quantitate these biomolecules.
J. M. Sutton   +4 more
semanticscholar   +1 more source

Circular Oligonucleotides: New Concepts in Oligonucleotide Design

Annual Review of Biophysics and Biomolecular Structure, 1996
Recent progress in the synthesis and properties of circular oligonucleotides as ligands for DNA and RNA and as templates for polymerase enzymes is described. Small synthetic circular DNAs, RNAs, and chimeric analogues ranging from 28 to 74 nucleotides in size have been synthesized with the use of a nonenzymatic ligation strategy.
openaire   +2 more sources

Home - About - Disclaimer - Privacy